drugset
drugset / Trial / NCT02539849

Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease

NCT02539849 ↗

Completed 38 enrolled Hospital Universitari Vall d'Hebron Research Institute AbbVie · collab
NaSingle-groupOpen-labelOther

Summary

FOS improve gut colonization by Faecalibacterium prausnitzii in patients with Crohn's disease

Timeline

Start
2014-12
Primary completion
2017-12-19
Completion
2017-12-19

Drugs

EvaluationDrugModalityDoseRoute
Background Adalimumab Monoclonal antibody — —

Indications

Crohn disease